Posttranslational modifications of FOXO1 regulate epidermal growth factor receptor tyrosine kinase inhibitor resistance for non-small cell lung cancer cells
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Posttranslational modifications of FOXO1 regulate epidermal growth factor receptor tyrosine kinase inhibitor resistance for non-small cell lung cancer cells
Authors
Keywords
FOXO1, Acetylation, TKI resistance, NSCLC
Journal
TUMOR BIOLOGY
Volume 36, Issue 7, Pages 5485-5495
Publisher
Springer Nature
Online
2015-06-03
DOI
10.1007/s13277-015-3215-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Acetylation of FoxO1 Activates Bim Expression to Induce Apoptosis in Response to Histone Deacetylase Inhibitor Depsipeptide Treatment
- (2015) Yang Yang et al. NEOPLASIA
- Targeting TORC1/2 Enhances Sensitivity to EGFR Inhibitors in Head and Neck Cancer Preclinical Models
- (2015) Andre Cassell et al. NEOPLASIA
- mTOR Complex 2 Controls Glycolytic Metabolism in Glioblastoma through FoxO Acetylation and Upregulation of c-Myc
- (2013) Kenta Masui et al. Cell Metabolism
- Targeting mTOR to Overcome Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer Cells
- (2013) Shi-Jiang Fei et al. PLoS One
- Combination of mTOR and EGFR Kinase Inhibitors Blocks mTORC1 and mTORC2 Kinase Activity and Suppresses the Progression of Colorectal Carcinoma
- (2013) Quan Wang et al. PLoS One
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- mTOR links oncogenic signaling to tumor cell metabolism
- (2011) Jessica L. Yecies et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Oncogenic EGFR Signaling Activates an mTORC2-NF- B Pathway That Promotes Chemotherapy Resistance
- (2011) K. Tanaka et al. Cancer Discovery
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- (2010) Alexa B. Turke et al. CANCER CELL
- Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapy
- (2010) Gur Pines et al. FEBS LETTERS
- Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer
- (2010) Gregory J. Riely Journal of Thoracic Oncology
- Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
- (2009) Juan M. García-Martínez et al. BIOCHEMICAL JOURNAL
- mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice
- (2009) David A. Guertin et al. CANCER CELL
- Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer
- (2009) T. Yamada et al. CLINICAL CANCER RESEARCH
- Targeting the mTOR Signaling Network for Cancer Therapy
- (2009) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular mechanisms of mTOR-mediated translational control
- (2009) Xiaoju Max Ma et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Common corruption of the mTOR signaling network in human tumors
- (2009) S Menon et al. ONCOGENE
- The Pharmacology of mTOR Inhibition
- (2009) D. A. Guertin et al. Science Signaling
- Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
- (2008) K Tamura et al. BRITISH JOURNAL OF CANCER
- Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling
- (2008) Tsuneo Ikenoue et al. EMBO JOURNAL
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now